A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to...
A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis
About this item
Full title
Author / Creator
Publisher
New York, NY: Elsevier Inc
Journal title
Language
English
Formats
Publication information
Publisher
New York, NY: Elsevier Inc
Subjects
More information
Scope and Contents
Contents
A previous phase II trial demonstrated that the fully human anti-IL-12/23 mAb briakinumab was efficacious in moderate-to-severe psoriasis. A subsequent 52-week, double-blind, placebo-controlled phase III study evaluated induction and maintenance treatment. Patients were randomized 2:1 to briakinumab (200mg at weeks 0 and 4 and 100mg at week 8) or p...
Alternative Titles
Full title
A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_916150409
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_916150409
Other Identifiers
ISSN
0022-202X
E-ISSN
1523-1747
DOI
10.1038/jid.2011.304
